This study revealed that serum lipocalin 2 levels decrease in breast cancer patients with increased tumor expression of the ER and PR receptors, it also indicates the collaboration and the cross-talk of iron transport proteins to deliver it to cancer cells. This evidence concerns the gene LCN2 and breast carcinoma.